Clinical Trial: Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

U.S., Dec. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07269470) titled 'Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase' on Nov. 26.

Brief Summary: The goal of this clinical research study is to find out if treatment with a combination of dasatinib plus ropeginterferon can help to control CML-CP. The safety of this combination will also be studied.

Study Start Date: May 01, 2026

Study Type: INTERVENTIONAL

Condition: Chronic Myeloid Leukemia

Intervention: DRUG: Dasatinib

Given orally daily for 3 cycles

DRUG: Ropeginterferon alfa-2b (P1101)

Given subcutaneous through injecti...